Science

ESMO Global Consortium Study on the availability and accessibility of cancer medicines

Nathan I. Cherny/szmc.org

Jan 16, 2025, 23:54

ESMO Global Consortium Study on the availability and accessibility of cancer medicines

The European Society for Medical Oncology (ESMO) shared a recent article by N.I. Cherny et al. on X:

“The results of the ESMO Global Consortium Study on the availability, out-of-pocket costs, and accessibility of cancer medicines are now available in Annals of Oncology with the latest 2023 update.”

“ESMO Global Consortium Study on the availability, out-of-pocket costs, and accessibility of cancer medicines: 2023 update“

Authors: N.I. Cherny, D. Trapani, M. Galotti, M. Saar, G. Bricalli, F. Roitberg, B. Gyawali, G. Curigliano, J.-Y. Blay, K. Meier, N.J. Latino4 and E.G.E. de Vries

ESMO Global Consortium Study

More posts featuring The European Society for Medical Oncology.

cancer cancer medicines D. Trapani E.G.E. de Vries ESMO Global Consortium Study European Society for Medical Oncology F. Roitberg G. Bricalli M. Galotti M. Saar N.I. Cherny OncoDaily Oncology

Oncologist Near Me - Vivek Subbiah: Pionner of Precision Oncology

Monica Bertagnolli is ending her tenure as NIH director

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

Special Coverage